Verastem Inc (FRA:2VSA)
€ 3.7 -0.34 (-8.42%) Market Cap: 158.44 Mil Enterprise Value: 109.90 Mil PE Ratio: 0 PB Ratio: 13.49 GF Score: 32/100

Verastem Inc at Stifel Targeted Oncology Days (Virtual) Transcript

Apr 25, 2023 / 06:30PM GMT
Release Date Price: €3.41 (-0.70%)
Ben Burnett
Stifel Financial Corp. - Analyst

Okay. Welcome, everyone, to our next session. I'm pleased to have Verastem Oncology with us today. It is a company focused developing medicines to treat RAS pathway driven cancers. And we have with us today, CEO, Brian Stuglik. And Brian, I'll pass it over to you for a presentation.

Brian Stuglik
Verastem, Inc. - CEO

Thank you very much, Ben, for hosting today, and I look forward to providing an update on the progress we've been making at Verastem Oncology. Really like to touch upon three things during the presentation. Just a quick overview of the company, a data recap in terms of the most recent data we did that put out earlier this year, and then talk about some upcoming inflection points for the second quarter of this year and the remainder of the year. Obviously, I will be making forward-looking statements today. So I would just refer listeners to our website for our risk factors.

Verastem Oncology is well-positioned to capitalize on what we believe is a very good growth opportunity. Our lead

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot